Organisation paid for research Program year 2025 Source: CMS Open Payments

Essential Medical Research, LLC

Neither a doctor nor a teaching hospital

Research payments

$701,788

83 payments

Through program year 2025, Essential Medical Research, LLC is reported as receiving $701,788 in research payments, across 83 payments.

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$32,865	2
2024	Research	$99,548	25
2023	Research	$91,062	10
2022	Research	$220,525	12
2021	Research	$257,788	34

Breakdown

Who paid Research payments · program years 2021–2025

Ucb SA $236,702 35 payments
Celgene Corporation $217,741 18 payments
Amgen Inc. $128,952 7 payments
Sanofi US Services Inc. $50,863 13 payments
Novartis Pharmaceuticals Corporation $32,365 2 payments
Navidea Biopharmaceuticals, Inc. $15,400 3 payments
Genzyme Corporation $12,100 3 payments
E.R. Squibb & Sons, L.L.C. $7,666 2 payments

Studies the money was for Research payments · program years 2021–2025

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa $162,134 8 payments
PhIII Yellowstone Induction Study # 2 OZANIMOD in Moderate to Severe CD (RPC01-3202) $78,656 5 payments
A Phase 3, open-label, parallel group, multicenter, extension study evaluating the long-term treatment of bimekizumab in study participants with moderate to severe hidradenitis suppurativa $74,568 27 payments
Ph3 Otezla in Peds mod/sev PsO (SPROUT) $66,292 2 payments
A Phase 3, Multicenter, Open-Label Extension Study $43,630 2 payments
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years S $32,365 2 payments
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD $30,737 9 payments
Ppso-003/20200056 (Sprout) $22,827 2 payments
Ph III Yellowstone CD OLE (RPC01-3204) - A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn s Disease $22,046 3 payments
Induction Study #2 - A Phase 3, Multicenter, Rando $19,480 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.